Drug Profile
Tenofovir disoproxil fumarate - BrightGene Bio-Medical Technology/Jiangsu Chia Tai Tianqing Pharmaceutical
Alternative Names: QingzhongLatest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator BrightGene Bio-medical technology
- Developer Chia Tai Tianqing Pharmaceutical Group
- Class Antiretrovirals; Antivirals; Phosphonic acids; Purines; Small molecules
- Mechanism of Action Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Hepatitis B
Most Recent Events
- 09 Nov 2018 Tenofovir Disoproxil Fumarate is still in phase III trial for Hepatitis B in China (NCT02287857)
- 09 Nov 2018 Safety and efficacy data from a phase III trial in hepatitis B presented at the 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2018)
- 28 Dec 2017 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-B in China (PO, Tablet)